A Long-term Follow-up Study of Patients Who Received MB-105
ConditionAny Patient Treated With MB-105
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorMarch Biosciences Inc
About this trial
This study is to fulfil the regulatory requirement for 15-year follow-up for patients treated with MB-105 in any study
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
None
Disqualifiers
None
Trial population
Patients who previously received MB-105 and consent to participate
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
MB-105
Biological/VaccineThis is an observational study with no study product administered because it is the LTFU study for patients who received the product in another study
Treatment groups
40 Participants
are divided into 1 treatment groupGroup A: Open Observation1 intervention
Trial outcomes
Primary outcomes
1
Assess long term safety of MB-105 in patients who received MB-105
SAEs
Time frame
15 YearsSecondary outcomes
1
Assess long term efficacy of MB-105 in patients who received MB-105
Time to progression/relapse in those who have not yet relapsed and overall survival
Time frame
15 YearsLocations
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov
This trial is not recruiting at the moment. You can still explore other options: